Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure.

Sharkey M, Babic DZ, Greenough T, Gulick R, Kuritzkes DR, Stevenson M.

PLoS Pathog. 2011 Feb;7(2):e1001303. doi: 10.1371/journal.ppat.1001303. Epub 2011 Feb 24.

2.

Deep molecular characterization of HIV-1 dynamics under suppressive HAART.

Buzón MJ, Codoñer FM, Frost SD, Pou C, Puertas MC, Massanella M, Dalmau J, Llibre JM, Stevenson M, Blanco J, Clotet B, Paredes R, Martinez-Picado J.

PLoS Pathog. 2011 Oct;7(10):e1002314. doi: 10.1371/journal.ppat.1002314. Epub 2011 Oct 27.

3.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
4.

In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA.

Sharkey M, Triques K, Kuritzkes DR, Stevenson M.

J Virol. 2005 Apr;79(8):5203-10.

5.

Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication.

Chun TW, Justement JS, Murray D, Hallahan CW, Maenza J, Collier AC, Sheth PM, Kaul R, Ostrowski M, Moir S, Kovacs C, Fauci AS.

AIDS. 2010 Nov 27;24(18):2803-8. doi: 10.1097/QAD.0b013e328340a239.

6.

Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus.

Tobin NH, Learn GH, Holte SE, Wang Y, Melvin AJ, McKernan JL, Pawluk DM, Mohan KM, Lewis PF, Mullins JI, Frenkel LM.

J Virol. 2005 Aug;79(15):9625-34.

7.

Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy.

Sharkey ME, Teo I, Greenough T, Sharova N, Luzuriaga K, Sullivan JL, Bucy RP, Kostrikis LG, Haase A, Veryard C, Davaro RE, Cheeseman SH, Daly JS, Bova C, Ellison RT 3rd, Mady B, Lai KK, Moyle G, Nelson M, Gazzard B, Shaunak S, Stevenson M.

Nat Med. 2000 Jan;6(1):76-81.

PMID:
10613828
8.

Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.

Price DA, Scullard G, Oxenius A, Braganza R, Beddows SA, Kazmi S, Clarke JR, Johnson GE, Weber JN, Phillips RE.

J Virol. 2003 May;77(10):6041-9.

9.

Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.

Pariente N, Pernas M, de la Rosa R, Gómez-Mariano G, Fernández G, Rubio A, López M, Benito JM, López-Galíndez C, Leal M, Domingo E, Martinez MA, Mas A.

J Med Virol. 2004 Jul;73(3):350-61.

PMID:
15170628
10.

The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy.

Lerner P, Guadalupe M, Donovan R, Hung J, Flamm J, Prindiville T, Sankaran-Walters S, Syvanen M, Wong JK, George MD, Dandekar S.

J Virol. 2011 May;85(10):4772-82. doi: 10.1128/JVI.02409-10. Epub 2011 Feb 23.

11.

Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211).

Crawford KW, Li C, Keung A, Su Z, Hughes MD, Greaves W, Kuritzkes D, Gulick R, Flexner C; ACTG A5211 Study Team.

J Acquir Immune Defic Syndr. 2010 Apr;53(5):598-605. doi: 10.1097/QAI.0b013e3181c9caac.

12.

Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy.

Zhang L, Chung C, Hu BS, He T, Guo Y, Kim AJ, Skulsky E, Jin X, Hurley A, Ramratnam B, Markowitz M, Ho DD.

J Clin Invest. 2000 Oct;106(7):839-45.

13.
14.

CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy.

Boulassel MR, Chomont N, Pai NP, Gilmore N, Sékaly RP, Routy JP.

J Clin Virol. 2012 Jan;53(1):29-32. doi: 10.1016/j.jcv.2011.09.018. Epub 2011 Oct 22.

PMID:
22019250
15.

The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution.

Lambotte O, Chaix ML, Gubler B, Nasreddine N, Wallon C, Goujard C, Rouzioux C, Taoufik Y, Delfraissy JF.

AIDS. 2004 May 21;18(8):1147-58.

PMID:
15166530
16.

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

Buzón MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, Gatell JM, Domingo P, Paredes R, Sharkey M, Palmer S, Stevenson M, Clotet B, Blanco J, Martinez-Picado J.

Nat Med. 2010 Apr;16(4):460-5. doi: 10.1038/nm.2111. Epub 2010 Mar 14.

PMID:
20228817
17.

Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy.

Frenkel LM, Wang Y, Learn GH, McKernan JL, Ellis GM, Mohan KM, Holte SE, De Vange SM, Pawluk DM, Melvin AJ, Lewis PF, Heath LM, Beck IA, Mahalanabis M, Naugler WE, Tobin NH, Mullins JI.

J Virol. 2003 May;77(10):5721-30.

18.

Anti-human immunodeficiency virus type 1 humoral immune response and highly active antiretroviral treatment.

Bongertz V, Ouverney EP, Fernandez SC, Grinsztejn B, Veloso V, Couto-Fernandez JC, Pilotto JH, Morgado MG.

Mem Inst Oswaldo Cruz. 2007 Nov;102(7):817-25. Epub 2007 Dec 11.

19.

HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.

Goujard C, Girault I, Rouzioux C, Lécuroux C, Deveau C, Chaix ML, Jacomet C, Talamali A, Delfraissy JF, Venet A, Meyer L, Sinet M; ANRS CO6 PRIMO Study Group.

Antivir Ther. 2012;17(6):1001-9. doi: 10.3851/IMP2273. Epub 2012 Aug 6.

PMID:
22865544
20.

HIV-1 DNA and RNA kinetics in primary HIV infection.

Lillo F, Grasso M, Lodini S, Capiluppi B, Lazzarin A, Tambussi G.

J Biol Regul Homeost Agents. 2002 Jan-Mar;16(1):49-52.

PMID:
12003174
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk